Circulating immune signatures across clinical stages of chronic pancreatitis: a pilot study.

Autor:	Hagn-Meincke R; Centre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark.; Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California., Hart PA; Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, Ohio., Andersen DK; Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland., Vege SS; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota., Fogel EL; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana., Serrano J; Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland., Bellin MD; Division of Pediatric Endocrinology, University of Minnesota, Minneapolis, Minnesota., Topazian MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota., Conwell DL; Department of Medicine, University of Kentucky, Lexington, Kentucky., Li L; Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas., Van Den Eeden SK; Division of Research, Kaiser Permanente Northern California, Oakland., Drewes AM; Centre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark., Pandol SJ; Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, California., Forsmark CE; Division of Gastroenterology, Hepatology, and Nutrition. University of Florida, Gainesville, Florida., Fisher WE; Division of General Surgery, Baylor College of Medicine, Houston, Texas., Yadav D; Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Olesen SS; Centre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark., Park WG; Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Jazyk:	angličtina
Zdroj:	European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2024 Feb 01; Vol. 36 (2), pp. 177-183. Date of Electronic Publication: 2023 Nov 30.
DOI:	10.1097/MEG.0000000000002691
Abstrakt:	Objective: This pilot study seeks to identify serum immune signatures across clinical stages of patients with chronic pancreatitis (CP). Methods: We performed a cross-sectional analysis of prospectively collected serum samples from the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translation StuDies-study. CP subjects were categorised into three clinical stages based on the presence/absence of metabolic complications: (1) CP with no diabetes and exocrine pancreatic dysfunction (EPD), (2) CP with either diabetes or EPD, and (3) CP with diabetes and EPD. Blinded samples were analysed using an 80-plex Luminex assay of cytokines/chemokines/adhesion molecules. Group and pairwise comparisons were performed to characterise immune signatures across CP subgroups. Results: A total of 135 CP subjects (evenly distributed between clinical stages) and 50 controls were studied. Interleukin-6 (IL-6), interleukin-8 (IL-8), and soluble intercellular adhesion molecule 1 (sICAM-1) were significantly elevated in CP subjects compared to controls. The levels of IL-6 and IL-8 increased with advancing disease stages, with the highest levels observed in CP with diabetes and EPD (clinical stage 3). Furthermore, hepatocyte growth factor and macrophage-derived chemokine were significantly increased in clinical stage 3 compared to controls. Conclusion: Our study reveals a progressive elevation in pro-inflammatory cytokines and chemokines with advancing clinical stages of CP. These findings indicate potential targets for the development of disease-modifying interventions. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu